Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ. Qazilbash MH, et al. Among authors: alatrash g. Leukemia. 2017 Mar;31(3):697-704. doi: 10.1038/leu.2016.254. Epub 2016 Sep 22. Leukemia. 2017. PMID: 27654852 Free PMC article.
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.
Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Andersson BS, et al. Bone Marrow Transplant. 2017 Apr;52(4):580-587. doi: 10.1038/bmt.2016.322. Epub 2016 Dec 19. Bone Marrow Transplant. 2017. PMID: 27991894 Free PMC article. Clinical Trial.
Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Khouri IF, et al. Among authors: alatrash g. Bone Marrow Transplant. 2017 Jan;52(1):28-33. doi: 10.1038/bmt.2016.204. Epub 2016 Sep 5. Bone Marrow Transplant. 2017. PMID: 27595282 Free PMC article.
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.
Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Popat UR, et al. Lancet Haematol. 2018 Nov;5(11):e532-e542. doi: 10.1016/S2352-3026(18)30156-X. Lancet Haematol. 2018. PMID: 30389035 Free PMC article. Clinical Trial.
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia.
Yeh J, Pasvolsky O, Saliba RM, Figgins B, Wang C, Fang Z, Ahmed S, Yilmaz M, Daver N, Ravandi F, DiNardo C, Short NJ, Kadia T, Al-Atrash G, Daher M, Costa DM, Popat U, Champlin R, Shpall E, Oran B. Yeh J, et al. Clin Lymphoma Myeloma Leuk. 2024 Nov;24(11):e819-e826. doi: 10.1016/j.clml.2024.07.001. Epub 2024 Jul 25. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39183099
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
Montalban-Bravo G, Thongon N, Rodriguez-Sevilla JJ, Ma F, Ganan-Gomez I, Yang H, Kim YJ, Adema V, Wildeman B, Tanaka T, Darbaniyan F, Al-Atrash G, Dwyer K, Loghavi S, Kanagal-Shamanna R, Song X, Zhang J, Takahashi K, Kantarjian H, Garcia-Manero G, Colla S. Montalban-Bravo G, et al. Cell Rep Med. 2024 Jun 18;5(6):101585. doi: 10.1016/j.xcrm.2024.101585. Epub 2024 May 22. Cell Rep Med. 2024. PMID: 38781960 Free PMC article.
Hu8F4-CAR T cells with mutated Fc spacer segment improve target-specificity and mediate anti-leukemia activity in vivo.
Molldrem J, He H, Vedia R, Lu S, Li Q, Cox K, St John L, Sergeeva A, Clise-Dwyer K, Alatrash G, Shpall E, Ma Q. Molldrem J, et al. Among authors: alatrash g. Res Sq [Preprint]. 2024 Feb 19:rs.3.rs-3937972. doi: 10.21203/rs.3.rs-3937972/v1. Res Sq. 2024. Update in: Cytotherapy. 2024 Nov;26(11):1331-1340. doi: 10.1016/j.jcyt.2024.06.010 PMID: 38464203 Free PMC article. Updated. Preprint.
130 results